AdaptHealth Corp. (AHCO)
| Market Cap | 825.80M -31.4% |
| Revenue (ttm) | 3.36B +13.5% |
| Net Income | -227.60M |
| EPS | -1.68 |
| Shares Out | 133.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,614,813 |
| Open | 6.32 |
| Previous Close | 6.49 |
| Day's Range | 6.24 - 6.52 |
| 52-Week Range | 5.21 - 13.43 |
| Beta | 1.39 |
| Analysts | Strong Buy |
| Price Target | 9.14 (+47.66%) |
| Earnings Date | Aug 4, 2026 |
About AHCO
AdaptHealth Corp., together with its subsidiaries, distributes home medical equipment (HME), medical supplies, and home and related services in the United States. It operates through Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home segments. The company offers sleep therapy equipment, supplies, and related services, such as continuous positive airway pressure and BiLevel services to individuals suffering from obstructive sleep apnea; oxygen and home mechanical ventilation equipment and supplies and related chronic therapy... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for AHCO stock is "Strong Buy." The 12-month stock price target is $9.14, which is an increase of 47.66% from the latest price.
News
AdaptHealth names Harriss Currie as new CFO
AdaptHealth (AHCO) announced that its Board of Directors has named Harriss T. Currie as its Chief Financial Officer, effective September 9, 2026. Mr. Currie will assume CFO responsibilities from Jason...
AdaptHealth Appoints Harriss Currie as Chief Financial Officer
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home ...
ReDream Brands Launches as the Leading Direct-to-Consumer Platform for Sleep Apnea and Sleep Health
New platform brings four of the industry's most recognized direct-to-consumer brands together to serve the cash-pay obstructive sleep apnea (OSA) market across North America NEW YORK, Aug. 17, 2026 /P...
AdaptHealth Corp. Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Personal Information
CONSHOHOCKEN, Pa., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from the AdaptHealth Corp. (Nasdaq: AHCO) data...
AdaptHealth Transcript: Canaccord Genuity's 46th Annual Growth Conference
The business completed a major portfolio shift, exiting diabetes and e-commerce to focus on sleep and respiratory, driving strong growth and record referrals. Technology investments and a large West Coast capitated contract are key growth drivers, with capital prioritized for organic expansion and debt reduction.
AHCO Investors Have Opportunity to Join AdaptHealth Corp. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $AHCO--AHCO Investors Have Opportunity to Join AdaptHealth Corp. Fraud Investigation with SBS Law.
AdaptHealth Corp. to Participate in Upcoming Investor Conferences
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medi...
AdaptHealth price target lowered to $10 from $14 at UBS
UBS analyst Kevin Caliendo lowered the firm’s price target on AdaptHealth (AHCO) to $10 from $14 and keeps a Buy rating on the shares.
AdaptHealth price target lowered to $8 from $15 at RBC Capital
RBC Capital lowered the firm’s price target on AdaptHealth (AHCO) to $8 from $15 and keeps an Outperform rating on the shares.
AdaptHealth price target lowered to $9 from $14 at Truist
Truist lowered the firm’s price target on AdaptHealth (AHCO) to $9 from $14 and keeps a Buy rating on the shares. The Q2 results disappointed due to contract, portfolio, and…
AdaptHealth price target lowered to $10 from $15 at Baird
Baird analyst Eric Coldwell lowered the firm’s price target on AdaptHealth (AHCO) to $10 from $15 and keeps an Outperform rating on the shares.
AdaptHealth price target lowered to $10 from $16 at Canaccord
Canaccord lowered the firm’s price target on AdaptHealth (AHCO) to $10 from $16 and keeps a Buy rating on the shares. The firm updated its model following disappointing Q2 results…
AdaptHealth Earnings Call Transcript: Q2 2026
Organic growth reached 16% with strong gains in Sleep and Respiratory Health, but profitability was pressured by West Coast contract inefficiencies and a sudden supplier price hike. Strategic divestitures and restructuring are expected to improve margins and focus future growth.
AdaptHealth Earnings release: Q2 2026
AdaptHealth released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
AdaptHealth Slides: Q2 2026
AdaptHealth has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
AdaptHealth Quarterly report: Q2 2026
AdaptHealth has published its Q2 2026 quarterly earnings report on August 4, 2026.
AdaptHealth lowers FY26 revenue view to $2.85B-$2.89B from $3.45B-$3.52B
Consensus $3.49B. The company said, “The Company is revising its financial guidance for fiscal year 2026 on a continuing operations basis, which excludes the Diabetes Health business, except for free…
AdaptHealth reports Q2 EPS ($1.07) vs. 3c last year
Reports Q2 revenue $740.3M vs. $657.1M last year. “In the second quarter, we delivered 15.9% organic growth, with record volume gains across the business,” said Suzanne Foster, Chief Executive Officer...
AdaptHealth Corp. Announces Second Quarter 2026 Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medi...
AdaptHealth upgraded to Buy at Jefferies on improved growth, earnings visibility
As previously reported, Jefferies upgraded AdaptHealth (AHCO) to Buy from Hold with a price target of $13, up from $11. With its underperforming diabetes business divested, just as the core…
AdaptHealth upgraded to Buy from Hold at Jefferies
Jefferies upgraded AdaptHealth (AHCO) to Buy from Hold with a price target of $13, up from $11.
Cardinal Health to buy AdaptHealth diabetes unit, Strive Medical for $360 million
Cardinal Health said on Monday it has agreed to buy AdaptHealth's diabetes health business and medical supply provider Strive Medical in separate deals for about $360 million in total, expanding its...
Cardinal to acquire Diabetes business of AdaptHealth, Strive Medical for $360M
Cardinal Health (CAH) announced it has entered into two definitive agreements. Cardinal Health will acquire the Diabetes Health business of AdaptHealth (AHCO), and, in its entirety, Strive Medical, a ...
Cardinal Health expands home care business with two tuck-in acquisitions
DUBLIN, Ohio, July 20, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today it has entered into two definitive agreements that accelerate its at-Home Solutions' growth strategy. Cardinal H...
AdaptHealth to divest diabetes health business to Cardinal Health for $235M
AdaptHealth Corp. (AHCO) that it is divesting its Diabetes Health business to Cardinal Health (CAH). Under the terms of an agreement signed July 19, 2026, Cardinal Health will acquire AdaptHealth’s…